Cocrystal Pharma (COCP) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 14.4% versus a loss of 44.4%. Over five years, COCP leads with a -90.5% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($21.9 million vs $20.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | QNRX |
|---|---|---|
| Share price | $1.07 | $4.55 |
| Market cap | $20.61M | $21.86M |
| 1-day change | 0.00% | -3.19% |
| YTD return | +9.18% | -68.47% |
| 1-year return | -14.40% | -44.44% |
| 5-year return | -90.51% | -99.99% |
| EPS (TTM) | $-0.76 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $41.80 |
| 52-week low | $0.76 | $3.25 |
| Distance from 52-week high | -47.29% | -89.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +741.12% | +379.78% |
| Average volume | 56.00K | 541.61K |
| Shares outstanding | 19.26M | 4.80M |
| Employees | 10 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed QNRX by 30.0 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Healthcare · Biotechnology · 10 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Healthcare · Biotechnology · 4 employees
COCP vs QNRX FAQ
Which is bigger, Cocrystal Pharma or Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $21.86M compared with $20.61M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, COCP or QNRX?
COCP returned -14.40% over the past 12 months, compared with -44.44% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.